The historic rise of Viagra has long been a benchmark of pharmaceutical success, but its legacy within the broader market now triggers questions about future gains. Generic versions are undercutting exclusivity , prompting concerns that investing in companies closely tied to Viagra's once-dominant standing could be a dangerous move , especially giv